SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a biopharmaceutical company
developing cancer stem cell-related technologies, today announced that the
Company's stock will trade on OTCQX International under the symbol "SCTPF"
starting May 20. OTCQX is the premier U.S. Over-The-Counter marketplace,
allowing international companies increased access and exposure to the U.S.
market. 


Roth Capital Partners will be the market maker for Stem Cell Therapeutics' stock
and will also serve as the Company's Principal American Liaison (PAL) on OTCQX,
responsible for providing guidance on OTCQX requirements and U.S. securities
laws. Roth Capital Partners is an investment banking firm dedicated to the
small-cap public market and has been an innovator in this market since its
inception in 1984.


"The U.S. capital markets are critically important in assuring viability of life
sciences companies internationally and we undertake this step as part of a
deliberate and long-term strategy," commented Stem Cell Therapeutics' Chairman
David Allan. "The admission to the OTCQX is one of several undertakings that the
company committed to complete this year. The acquisition of Trillium, the
in-licensing of the tigecycline program and the recent completion of dosing in
the interstitial cystitis trial are among the others."


About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT), a Toronto-based biopharmaceutical company,
is Canada's only public company dedicated to advancing cancer stem cell
discoveries into novel and innovative cancer therapies. Building on over half a
century of leading and groundbreaking Canadian stem cell research, the company
is supported by established links to multiple Toronto academic institutes and
oncology treatment centers that represent one of the world's most acclaimed
cancer research hubs. SCT's lead clinical program, which targets a metabolic
pathway in leukemia blasts and leukemic stem cells, is currently being evaluated
in a multi-centre Phase I study in patients with relapsed or refractory Acute
Myeloid Leukemia (AML). The Company also has two premier preclinical programs,
SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key
immunoregulatory pathways that tumor cells exploit to evade the host immune
system. SIRPaFc is an antibody-like fusion protein that blocks the activity of
CD47, a molecule that is upregulated on cancer stem cells in AML and several
other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the
activity of CD200, an immunosuppressive molecule that is overexpressed by many
hematopoietic and solid tumors. For more information, visit:
www.stemcellthera.com


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
Dr. Niclas Stiernholm
Chief Executive Officer
+1 416 595 0627
niclas@stemcellthera.com
www.stemcellthera.com

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Sunvest Minerals Corp (TSXV:SSS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024